Literature DB >> 20709663

Surveillance computed tomography scans for patients with lymphoma: is the risk worth the benefits?

Pareen Shenoy1, Rajni Sinha, John W Tumeh, Mary Jo Lechowicz, Christopher R Flowers.   

Abstract

BACKGROUND: Concerns regarding the risks of cancer and cancer-related death as a result of radiation from computed tomography (CT) scans and the lack of data demonstrating a survival advantage for surveillance CT scans following lymphoma therapy have raised questions regarding their benefit. We compared the radiation-related lifetime cancer incidence (LCI) and mortality risks (LCMRs) associated with CT scans for staging and surveillance of non-Hodgkin lymphoma (NHL) and Hodgkin lymphoma (HL) with the cumulative probability of lymphoma death (CPLD) during surveillance. PATIENTS AND METHODS: The LCI and LCMR were calculated using published estimates of the cumulative organ-specific radiation doses from full-body CT scans and sex-, age-, and organ-dependent cancer risks per 0.1 Gy provided by the Biologic Effects of Ionizing Radiations VII report. Surveillance, Epidemiology, and End Results (SEER) data were used to identify cases between 2000 and 2006 from 17 SEER registries and calculate CPLD for specified cohorts.
RESULTS: For a 70-year-old patient, a single full-body CT examination is associated with a LCI of 0.044% and 0.057%, and a LCMR of 0.032% and 0.044% for males and females, respectively. For 20-year-old patients the LCMRs were 0.071% for men and 0.108% for women. The LCI and LCMR were lower for males and were markedly less than the CPLD at 5 years for most lymphoma subtypes, but relevant for younger women with HL.
CONCLUSION: Although the LCMR from CT scans is small compared with lymphoma-related deaths for most subgroups, these data should be discussed with patients in formulating plans for surveillance following lymphoma therapy.

Entities:  

Mesh:

Year:  2010        PMID: 20709663     DOI: 10.3816/CLML.2010.n.056

Source DB:  PubMed          Journal:  Clin Lymphoma Myeloma Leuk        ISSN: 2152-2669


  13 in total

1.  My treatment approach to patients with diffuse large B-cell lymphoma.

Authors:  James O Armitage
Journal:  Mayo Clin Proc       Date:  2012-02       Impact factor: 7.616

2.  Utility of routine post-therapy surveillance imaging in diffuse large B-cell lymphoma.

Authors:  Carrie A Thompson; Herve Ghesquieres; Matthew J Maurer; James R Cerhan; Pierre Biron; Stephen M Ansell; Catherine Chassagne-Clément; David J Inwards; Thérèse Gargi; Patrick B Johnston; Emmanuelle Nicolas-Virelizier; William R Macon; Marie Peix; Ivana N Micallef; Catherine Sebban; Grzegorz S Nowakowski; Luis F Porrata; George J Weiner; Thomas E Witzig; Thomas M Habermann; Brian K Link
Journal:  J Clin Oncol       Date:  2014-09-29       Impact factor: 44.544

3.  Noninvasive monitoring of diffuse large B-cell lymphoma by immunoglobulin high-throughput sequencing.

Authors:  David M Kurtz; Michael R Green; Scott V Bratman; Florian Scherer; Chih Long Liu; Christian A Kunder; Kazuhiro Takahashi; Cynthia Glover; Colm Keane; Shingo Kihira; Brendan Visser; Jason Callahan; Katherine A Kong; Malek Faham; Karen S Corbelli; David Miklos; Ranjana H Advani; Ronald Levy; Rodney J Hicks; Mark Hertzberg; Robert S Ohgami; Maher K Gandhi; Maximilian Diehn; Ash A Alizadeh
Journal:  Blood       Date:  2015-04-17       Impact factor: 22.113

4.  Considerations in the initial management of follicular lymphoma.

Authors:  Loretta Nastoupil; Rajni Sinha; Auldyn Hirschey; Christopher R Flowers
Journal:  Community Oncol       Date:  2012-11-01

Review 5.  Evaluating surveillance imaging for diffuse large B-cell lymphoma and Hodgkin lymphoma.

Authors:  Jonathon B Cohen; Madhusmita Behera; Carrie A Thompson; Christopher R Flowers
Journal:  Blood       Date:  2016-12-12       Impact factor: 22.113

Review 6.  Next-generation surveillance strategies for patients with lymphoma.

Authors:  Jonathon B Cohen; David M Kurtz; Ashley D Staton; Christopher R Flowers
Journal:  Future Oncol       Date:  2015       Impact factor: 3.404

Review 7.  Positron emission tomographic scans in lymphoma: convention and controversy.

Authors:  Stephen M Ansell; James O Armitage
Journal:  Mayo Clin Proc       Date:  2012-06       Impact factor: 7.616

Review 8.  Whole body magnetic resonance in indolent lymphomas under watchful waiting: The time is now.

Authors:  Massimo Galia; Domenico Albano; Corrado Tarella; Caterina Patti; Luca Maria Sconfienza; Antonino Mulè; Pierpaolo Alongi; Massimo Midiri; Roberto Lagalla
Journal:  Eur Radiol       Date:  2017-10-10       Impact factor: 5.315

9.  Lack of usefulness of computed tomography for surveillance in patients with aggressive non-Hodgkin lymphoma.

Authors:  Ka-Won Kang; Se Ryeon Lee; Dae Sik Kim; Eun Sang Yu; Hwa Jung Sung; Seok Jin Kim; Chul Won Choi; Yong Park; Byung Soo Kim
Journal:  PLoS One       Date:  2018-02-14       Impact factor: 3.240

10.  Surveillance imaging during first remission in follicular lymphoma does not impact overall survival.

Authors:  Max L Goldman; Jimmy J Mao; Christopher S Strouse; Wanqi Chen; Manali Rupji; Zhengjia Chen; Matthew J Maurer; Oscar Calzada; Michael Churnetski; Christopher R Flowers; James R Cerhan; Brian K Link; Carrie A Thompson; Jonathon B Cohen
Journal:  Cancer       Date:  2021-06-22       Impact factor: 6.921

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.